Nanomedicine against multidrug resistance in cancer treatment

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond.)5,597–615 (2010).▪▪ Outstanding review of nanomedicinal strategies for multidrug resistance in cancer therapy.
  CASGoogle Scholar
• 2  Shapira A, Livney YD, Broxterman HJ. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat.14,150–163 (2011).▪▪ Comprehensive review reporting nanomedicines to overcome drug resistance in cancer therapy.
  Medline CASGoogle Scholar
• 3  Dean M, Fojo T, Bates S. Tumor stem cells and drug resistance. Nat. Rev. Cancer5,275–284 (2005).▪▪ Excellent review article describing the relationship of cancer stem cells and drug resistance.
  Medline CASGoogle Scholar
• 4  Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol. Oncol. Clin. North Am.9,451–473 (1995).
  Medline CASGoogle Scholar
• 5  Shannon AM, Bouchier-Hayes DJ, Condron CM. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev.29,297–307 (2003).
  Medline CASGoogle Scholar
• 6  Chen AM, Zhang M, Wei D. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small5,2673–2677 (2009).▪ Simultaneous delivery of doxorubicin and Bcl-2 siRNA using mesoporous silica nanoparticles showed significantly enhanced antitumor activity in multidrug-resistant cancer cells.
  Medline CASGoogle Scholar
• 7  Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism – a strategy for overcoming drug resistance. J. Natl. Cancer Inst.93,347–357 (2001).
  Medline CASGoogle Scholar
• 8  Meads MB, Gatenby RA, Dalton WS. Enviroment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer9,665–674 (2009).▪▪ Excellent review article regarding tumor environment and multidrug resistance.
  Medline CASGoogle Scholar
• 9  Wion D, Berger F. Cancer stem cells. N. Engl. J. Med.355,1253–1261 (2006).
  MedlineGoogle Scholar
• 10  Greenberg PL, Lee SJ, Advani R: Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a Phase III trial (E2995). J. Clin. Oncol.22,1078–1086 (2004).▪▪ Report about the pharmacokinetic interaction that exists between the chemotherapeutics and the ABC transporter inhibitors.
  Medline CASGoogle Scholar
• 11  Feng SS, Zhao LY, Tang JT. Nanomedicine for oral chemotherapy. Nanomedicine (Lond.)6(3),407–410 (2011).▪▪ Editorial for a short review on nanomedicine for oral chemotherapy in comparison with ABC transporter application.
  Google Scholar
• 12  Gao J, Feng SS, Guo Y. Antibody engineering promotes nanomedicine for cancer treatment. Nanomedicine (Lond.)5,1141–1145 (2010).▪ Classical editorial about the contribution of antibodies to nanomedicines in cancer therapy.
  CASGoogle Scholar
• 13  Chow EK, Zhang XQ, Chen M. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci. Transl. Med.3,73ra21 (2011).▪▪ Excellent work about nanodiamond-delivered doxorubicin in overcoming multidrug resistance in cancer.
  MedlineGoogle Scholar
• 14  Minko T, Kopeckova P, Kopecek J. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm. Res.16,986–996 (1999).
  Medline CASGoogle Scholar
• 15  Song XR, Cai Z, Zheng Y. Reversion of multidrug resistance by coencapsulation of vincristine and verapamil in PLGA nanoparticles. Eur. J. Pharm. Sci.37,300–305 (2009).
  Medline CASGoogle Scholar
• 16  Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm.6,928–939 (2009).
  Medline CASGoogle Scholar
• 17  Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev.61,721–731 (2009).
  Medline CASGoogle Scholar
• 18  Gao J, Yu Y, Zhang Y. EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma. Biomaterials33,270–282 (2012).▪▪ Excellent work regarding EGF receptor-specific immunoliposomes for siRNA-mediated gene silencing in hepatocellular carcinoma.
  Medline CASGoogle Scholar
• 19  Gao J, Liu W, Xia Y. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials32,3459–3470 (2011).
  Medline CASGoogle Scholar
• 20  Yadav S, van Vlerken LE, Little SR. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother. Pharmacol.63,711–722 (2009).
  Medline CASGoogle Scholar